RYAH Medtech says group granted US patent to utilize AI for the analysis of medical cannabis data

RYAH Medtech Inc, a privately-owned artificial intelligence (AI), big data and IoT device company focused on plant-based medicine dosing and analytics, announced that RYAH Group has been granted a patent to utilize AI for the analysis of medical cannabis data.

The company said that, with U.S. Patent # 10,296,714 – entitled “Method and system for medical cannabinoid treatment and product selection” – its big data platform will now use AI to better identify and understand correlations between plant strains and medical indications.

RYAH is currently processing 37 medical indications across medical databases and clinical trials. Additionally, information collected from RYAH’s dose-measuring devices is stored in RYAH’s HIPAA compliant database and processed using AI to produce fact-based decisions. 

Medical professionals, marketers, dispensaries, and other medical cannabis stakeholders will be able employ this database for research purposes, as it will feature anonymous, real-time patients’ feedback and accurate data.

Another step in long term strategy

Gregory Wagner, CEO of RYAH commented: “This patent is another step in our long-term strategy to be a market leader in creating a beneficial, predictive, enterprise data analytics solution in the medical plant industry.”

“We expect this patent to further validate our expanding IoT product suite and open future medical and business opportunities that allow professionals to make informed decisions from real time strain-related usage data. This patent ultimately confirms our dedication in using artificial intelligence and big data to potentially change lives,” he added.

RYAH’s data platform will use the latest technology, including AI, to streamline recommendation and prescription decision making process for both medical professionals and consumers.

It is believed that the database will become an attractive feature for a wide range of potential partners and collaborators, especially since the cannabis market is shifting to data driven decision making.

The group also has plans to expand to use its AI, big-data platform and IoT solutions into the growing nutraceutical market.

Easier purchasing for vaporizer

On Monday, RYAH revealed that it is making it easier for Canadian patients to purchase its dose-measuring dry herb vaporizer by partnering up with SOS Cannabis.

The partnership will provide patients with the opportunity for free legal representation from the team at SOS when seeking reimbursement from government agencies for the costs of purchasing the RYAH vaporizer.

The vaporizer lets patients precisely measure the dose and temperature of their vaporizing sessions and uses HIPAA-compliant medical data to analyze what works for them. RYAH Medtech is a privately-held company based in New York.

SOS Cannabis is a law firm based in Quebec that helps clients seek proactive and retroactive reimbursement for claims made to governmental organizations.

Story by ProactiveInvestors